Drug intelligence / Profile preview

oral mRNA COVID-19 vaccine

Development stage: Preclinical
Lead developer: Esperovax
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

The oral mRNA COVID-19 vaccine is a vaccine candidate developed by Esperovax. It is based on Esperovax's proprietary Egress RD™ platform, which utilizes engineered baker's yeast to deliver enveloped virus-like particles (eVLPs) to the gut. This vaccine aims to provide a needle-free, room-temperature-stable solution for rapid pandemic response, aligning with BARDA's "Beyond the Needle" initiative. It is currently undergoing preclinical feasibility studies.

Other names: Esperovax oral COVID-19 vaccineEgress RD mRNA vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on oral mRNA COVID-19 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oral mRNA COVID-19 vaccine.

Explore the full profile